Heather B. Allewelt

Hematology | Oncology
2501 N Orange Ave Ste 589
Orlando, FL 32804

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications

Zanubrutinib for the treatment of patients with del(17p) and/or TP53 CLL/SLL: analysis across clinical studies.

Zanubrutinib for the treatment of patients with del(17p) and/or TP53 CLL/SLL: analysis across clinical studies.

Journal: Blood advances
Published: January 22, 2025

Outcomes after transition from ibrutinib to zanubrutinib in patients with Waldenström macroglobulinemia from the ASPEN study.

Outcomes after transition from ibrutinib to zanubrutinib in patients with Waldenström macroglobulinemia from the ASPEN study.

Journal: Blood advances
Published: December 09, 2024

Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia.

Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia.

Journal: Blood advances
Published: August 12, 2024

Health-related quality of life in patients with Waldenström macroglobulinemia: results from the ASPEN trial.

Health-related quality of life in patients with Waldenström macroglobulinemia: results from the ASPEN trial.

Journal: Future oncology (London, England)
Published: July 29, 2024

Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study.

Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 21, 2023

Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia.

Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia.

Journal: Blood advances
Published: June 06, 2023

Zanubrutinib, Alone and in Combination With Tislelizumab, for the Treatment of Richter Transformation of Chronic Lymphocytic Leukemia.

Zanubrutinib, Alone and in Combination With Tislelizumab, for the Treatment of Richter Transformation of Chronic Lymphocytic Leukemia.

Journal: HemaSphere
Published: November 28, 2022

Zanubrutinib for the treatment of relapsed/refractory hairy cell leukemia.

Zanubrutinib for the treatment of relapsed/refractory hairy cell leukemia.

Journal: Blood advances
Published: September 20, 2022

Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma.

Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma.

Journal: Blood advances
Published: September 24, 2021

Outcomes of pediatric patients with therapy-related myeloid neoplasms.

Outcomes of pediatric patients with therapy-related myeloid neoplasms.

Journal: Bone marrow transplantation
Published: May 19, 2021

Survey of quality of life, phenotypic expression, and response to treatment in Krabbe leukodystrophy.

Survey of quality of life, phenotypic expression, and response to treatment in Krabbe leukodystrophy.

Journal: JIMD reports
Published: November 22, 2018

Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma.

Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma.

Journal: Leukemia research
Published: May 21, 2018
Showing 1-12 of 18

Last Updated: 09/26/2026